Intelligent Bio Solutions Inc. (INBS)vsNovartis AG ADR (NVS)
INBS
Intelligent Bio Solutions Inc.
$2.44
-3.94%
HEALTHCARE · Cap: $6.77M
NVS
Novartis AG ADR
$148.38
+3.30%
HEALTHCARE · Cap: $273.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1445687% more annual revenue ($56.58B vs $3.91M). NVS leads profitability with a 23.9% profit margin vs -296.8%. NVS earns a higher WallStSmart Score of 49/100 (D+).
INBS
Hold38
out of 100
Grade: F
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-23.2%
Fair Value
$4.26
Current Price
$2.44
$1.82 premium
Margin of Safety
-57.5%
Fair Value
$91.23
Current Price
$148.38
$57.15 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 45.5% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -170.2% — below average capital efficiency
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : INBS
The strongest argument for INBS centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 45.5% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : INBS
The primary concerns for INBS are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
INBS profiles as a hypergrowth stock while NVS is a declining play — different risk/reward profiles.
INBS carries more volatility with a beta of 4.24 — expect wider price swings.
INBS is growing revenue faster at 45.5% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 38/100), backed by strong 23.9% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Intelligent Bio Solutions Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Intelligent Bio Solutions Inc. (INBS) is a forward-thinking biotechnology firm specializing in the development of advanced diagnostic solutions and biomarker-driven technologies for drug abuse testing and monitoring. The company's innovative approach harnesses state-of-the-art scientific methodologies to deliver rapid and accurate testing options, enabling timely clinical decision-making and enhancing patient outcomes. As the demand for sophisticated diagnostic tools continues to rise, INBS is strategically positioned to lead the transformation of healthcare diagnostics, underscoring its commitment to improving healthcare quality and efficiency.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?